Director and 10% owner Scott R. Tobin filed a Form 4 with the SEC on November 9, 2026, disclosing the acquisition of stock options to purchase common stock of Champions Oncology, Inc. (NASDAQ:CSBR), with the earliest transaction date of November 5, 2026.

Key Highlights

  • Option grant: Scott R. Tobin acquired options to purchase 37,460 shares of Champions Oncology common stock on November 5, 2026.
  • Exercise price: The options carry an exercise price of $4.76 per share.
  • Expiration date: The options expire on November 5, 2036.
  • Vesting schedule: According to the filing, the options vest over a twelve-month period, with vesting occurring on November 5, 2026, February 5, 2027, May 5, 2027, and August 5, 2027.
  • Resulting ownership: Following the transaction, Tobin beneficially owns 37,460 derivative securities, held directly.
  • Roles: The filing identifies Tobin as both a director and a 10% owner of Champions Oncology, Inc.

Tobin Option Award Details: Champions Oncology November 2026 Grant

According to the Form 4 filed on November 9, 2026, Scott R. Tobin, identified in the filing as a director and 10% owner of Champions Oncology, Inc. (NASDAQ:CSBR), reported the acquisition of options to purchase 37,460 shares of the company's common stock. The transaction date was November 5, 2026, and the transaction code was recorded as "A," indicating an acquisition. No shares under Table I (non-derivative securities) were reported as acquired, disposed of, or changed in this filing.

The filing discloses that the options have an exercise price of $4.76 per share and an expiration date of November 5, 2036. The price of the derivative security at acquisition was also listed as $4.76. Per the explanation of responses included in the filing, "the options vest and are exercisable over a twelve month period, with vesting to occur on November 5, 2026, February 5, 2027, May 5, 2027 and August 5, 2027, respectively."

Following the reported transaction, Tobin's beneficial ownership of derivative securities stands at 37,460 options, held directly, according to the filing. The form was filed by one reporting person and was not indicated as an amendment to a prior filing. The filing was signed by Scott R. Tobin and dated November 9, 2026.

What Was Disclosed

Champions Oncology director and 10% owner Scott R. Tobin disclosed the acquisition of 37,460 options to purchase common stock at $4.76 per share, granted November 5, 2026, expiring November 5, 2036, and vesting in four installments over twelve months.